Hepatocellular carcinoma and colorectal cancer liver metastases often recur despite successful surgery. However, ctDNA-based recurrence detection presents a groundbreaking method for identifying minimal residual disease. This advanced technique tracks tumor-specific genetic mutations in the bloodstream. Consequently, it offers a more sensitive alternative to traditional imaging and standard protein biomarkers like alpha-fetoprotein.

Clinical Utility of ctDNA-based Recurrence Detection

A prospective randomized controlled trial will now investigate the efficacy of this monitoring tool. Specifically, the study aims to enroll 300 patients undergoing liver resection or transplantation. Researchers will compare ctDNA monitoring at baseline, one month, and six months against standard follow-up protocols. Furthermore, next-generation sequencing will establish baseline tumor mutation profiles to ensure high detection sensitivity.

Early data suggest that ctDNA status strongly predicts recurrence-free survival. For instance, patients with detectable post-operative ctDNA often experience significantly shorter survival times. In contrast, those with undetectable levels tend to have better long-term outcomes. Therefore, integrating liquid biopsies into routine clinical practice could revolutionize post-surgical surveillance.

Impact on Therapeutic Decision-Making

Early detection allows for swifter intervention and personalized therapy adjustments. This trial will assess various endpoints, including overall survival and patient-reported quality of life. Moreover, it will evaluate the cost-effectiveness of this approach compared to conventional surveillance. Ultimately, this research could lead to new standards of care for liver cancer patients worldwide.

What is ctDNA-based recurrence detection?

It is a liquid biopsy technique that identifies fragments of tumor DNA in the blood. This method helps detect cancer recurrence months before it appears on traditional CT or MRI scans.

Why is this trial important for liver surgery patients?

Liver cancer and colorectal metastases have very high recurrence rates after surgery. This trial investigates whether ctDNA monitoring can improve survival by allowing for earlier and more effective treatments.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.

References

1. Górzyńska I et al. Circulating tumor DNA-based assessment of disease progression after liver resection or transplantation for metastatic colorectal cancer or hepatocellular carcinoma-study protocol for a randomized, controlled trial. Trials. 2026 May 26. doi: 10.1186/s13063-026-09790-5. PMID: 42185926.


2. Wang S, et al. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study. Int J Surg. 2024;110(5):2713-2722. doi:10.1097/JS9.0000000000001236.


3. Wehrle CJ, et al. Tumor Mutational Burden from Circulating Tumor DNA Predicts Recurrence of Hepatocellular Carcinoma After Resection. Ann Surg. 2024.